ABvac 40

Drug Profile

ABvac 40

Alternative Names: ABvac40

Latest Information Update: 22 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Araclon Biotech
  • Class Alzheimer vaccines; Nootropics; Peptide vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease

Most Recent Events

  • 08 Feb 2018 Phase-II clinical trials in Alzheimer's disease in Sweden (SC) (EudraCT2016-004352-30)
  • 08 Feb 2018 Araclon Biotech initiates enrolment in a phase II trial for Alzheimer's disease in Spain (SC) (NCT03461276) (EudraCT2016-004352-30)
  • 27 Jun 2017 Spanish Agency of Medicinal Products and Medical Devices approves phase II clinical trials application for ABvac 40 in Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top